Shots:
- Aquestive’s Libervant buccal film (oral, 5mg, 7.5mg, 10mg, 12.5mg & 15mg) received the US FDA’s approval as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures), distinct from the usual pattern in epilepsy patients (2-5yrs.)
- The company further provided an update on Anaphylm (epinephrine) sublingual film, mentioning, its development is under progress for NDA submission, expected during the end of 2024
- The company is accepting & filling non-Medicaid prescriptions for libervant and will expand distribution in the upcoming wks. Libervant is a film formulation of diazepam that is administered buccally and developed as an acute treatment of frequent seizure episodes
Ref: Aquestive Therapeutics | Image: Aquestive Therapeutics| Press Release
Related News:- Pfizer’s BEQVEZ (fidanacogene elaparvovec-dzkt) Receives US FDA Approval for Adults with Hemophilia B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
